Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease.
Rosenson
Robert S
RS
Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA. rrosenso@med.umich.edu
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors*; D000818:Animals; D050197:Atherosclerosis / Q000201:enzymology / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology; D054497:Phospholipases A2, Secretory / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D055502:Secondary Prevention
D004791:Enzyme Inhibitors; D054497:Phospholipases A2, Secretory; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase